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Background: We sought to test the hypothesis that deficits in grey matter volume are characteristic of psychotic youth with early-onset
schizophrenia-spectrum disorders (EOSS) but not of psychotic youth with early-onset mood disorders (EOMD). Methods: We used mag-
netic resonance imaging to examine brain volume in 24 psychotic youth (13 male, 11 female) with EOSS (n = 12) or EOMD (n = 12) and
17 healthy controls (10 male, 7 female). We measured the volume of grey and white matter using an automated segmentation program.
Results: After adjustment for age and intracranial volume, whole brain volume was lower in the EOSS patients than in the healthy controls
(p = 0.001) and EOMD patients (p = 0.002). The EOSS patients had a deficit in grey matter volume (p = 0.005), especially in the frontal 
(p = 0.003) and parietal (p = 0.006) lobes, with no significant differences in white matter volume. Limitations: The main limitations of our
study were its small sample size and the inclusion of patients with depression and mania in the affective group. Conclusion: Adolescents
with EOSS have grey matter deficits compared with healthy controls and psychotic adolescents with EOMD. Our results suggest that grey
matter deficits are not generally associated with psychosis but may be specifically associated with schizophrenia. Larger studies with con-
sistent methods are needed to reconcile the contradictory findings among imaging studies involving psychotic youth.
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Introduction
Structural brain changes, particularly reductions in grey matter
volume, are well established in schizophrenia. A meta-analysis
of adults with first-episode schizophrenia found robust
changes in total brain volume and cerebrospinal fluid (CSF)
with more limited data indicating volumetric deficits in total
cortical grey matter and temporal grey matter.1 Recent studies
have consistently found grey matter deficits in patients with
first-episode schizophrenia2 and chronic schizophrenia.3 Youth
with treatment-resistant childhood-onset schizophrenia have
marked reductions in cortical grey matter, which are initially
present medially and posteriorly.4 Longitudinal volumetric
studies involving patients with childhood-onset schizophrenia
have shown progressive cortical changes that involve the entire
cortex within 5 years and then gradually become limited to the
frontal and temporal regions in early adulthood.5–10 It remains
unclear whether the structural changes observed in childhood-
onset, compared with adult-onset, schizophrenia are associated
with disruption of a neurodevelopmental process, as has been
suggested by some genetic studies.11–13 Alternatively, structural
changes could be associated with chronic illness, positive psy-
chotic symptoms, treatment resistance or a combination of
these factors. It is also unclear whether youth with more typical
adolescent-onset schizophrenia have grey matter changes of the
same magnitude and spatial extent as youth with childhood-
onset schizophrenia.
A review of longitudinal brain changes in childhood-onset
schizophrenia and adolescent-onset psychosis reported evi-
dence of increased CSF and reduced grey matter at diagnosis
in both disease states, but there is a lack of consensus about
progressive changes thereafter.5 Studies involving adolescents
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with schizophrenia have found increased fourth ventricle CSF
and reduced prefrontal cortex total, grey and white matter vol-
ume, but not reduced total brain volume at diagnosis.14,15
Among adolescents with undifferentiated psychosis, increases
in intracranial CSF and reductions in frontal grey matter have
been reported; these changes appear to be less severe than in
patients with childhood-onset schizophrenia.16
We asked whether the brain volume differences between
patients and controls are because of disease-specific neurode-
velopmental factors or chronic psychotic symptoms. One ap-
proach to answer this question is to compare structural brain
changes between adolescents with early-onset schizophrenia-
spectrum disorders (EOSS) and adolescents experiencing
positive psychotic symptoms as part of affective illness.
Youth with early-onset affective illness more often experience
psychotic symptoms than do individuals with adult-onset 
affective illness. Furthermore, the course of illness is often
more severe and long term in youth with mood disorders
than in patients with adult-onset mood disorders.
We sought to determine whether the brain changes ob-
served in youth experiencing psychotic symptoms in the con-
text of EOSS and early-onset mood disorders (EOMD) are
similar. Similarities would suggest that the greater brain
changes reported in patients with childhood-onset schizo-
phrenia relative to adult-onset schizophrenia are related to an
earlier onset of the psychotic process. Differences would sug-
gest that the brain changes in EOSS are unique to the patho-
physiology of schizophrenia, rather than being related to
psychosis or severe psychiatric illness.17
Few studies have directly compared cortical volume in
adults with schizophrenia to that in adults with other active
psychosis.18–25 These studies have not yielded consistent re-
sults, although differences in the brain regions studied and in
the specific diagnostic subtypes of the psychotic (nonschizo-
phrenic) groups may have contributed to disparate findings.
To assess the potential role of disrupted neurodevelopmen-
tal processes in the development of psychosis, it is important
to extend the studies comparing affective and schizophrenic
psychoses to adolescence, a time when psychotic symptoms
frequently begin and when normal neurodevelopmental
processes are highly active. We hypothesized that adolescents
with schizophrenia would have more pronounced grey mat-
ter deficits than those with affective psychoses or normal con-
trols. In this study, we tested the hypothesis that differences
in brain volume are associated specifically with schizophre-
nia, rather than with psychosis in general.
Methods
Participants 
We included adolescents with psychosis who were experi-
encing at least 1 positive psychotic symptom of moderate or
greater severity on the Brief Psychiatric Rating Scale for Chil-
dren;26 this symptom had to have been present for at least 
2 weeks. These criteria allowed for the inclusion of those with
a possible diagnoses of schizophrenia, schizoaffective disor-
der, major depression with psychotic features and bipolar af-
fective disorder with psychotic features. All diagnoses were
made on the basis of a medical record review, detailed clini-
cal examination by an adolescent psychiatrist (L.S.) and a
structured diagnostic interview administered by a social
worker or psychiatric nurse immediately after the youth en-
rolled in the study. All clinicians achieved 0.85 interrater reli-
ability on the New York University form of the Schedule for
Affective Disorders and Schizophrenia for School-Age Chil-
dren Present and Lifetime Version (K-SADS-PL)27 and on the
Structured Clinical Interview for DSM-IV (SCID).28 The 
K-SADS-PL and the psychotic disorders section of the SCID
were used for most participants, whereas the SCID alone was
used for participants older than 18 years (n = 3).
We excluded patients with psychotic symptoms that were
secondary to substance intoxication or withdrawal, those with
a full scale intelligence quotient less than 70, those with a con-
current diagnosis of pervasive developmental disorder, those
with any neurologic disorder, and those who were pregnant
or who posed imminent risk of harm to themself or others.
The psychotic adolescents were recruited on the basis of
participation in an ongoing antipsychotic treatment study in-
volving 50 youth with active psychosis. We recruited control
participants from the community through advertisement and
by word of mouth. Controls had no psychiatric disorder or
neurologic disease, as determined by K-SADS-PL and focused
neurologic examination. Controls and their guardians self-
reported that they had no first-degree relatives with a major
psychiatric disorder. Psychotic patients and controls were re-
cruited over a 3.5-year period. There was no change in the
scanner protocol during this period.
The protocol was approved by the Institutional Review
Board of the University of North Carolina. Each adolescent
gave written assent and each participant 18 years or older
gave written informed consent, as did all patient guardians.
Magnetic resonance imaging 
All magnetic resonance imaging (MRI) examinations were
performed on a 1.5-T Signa scanner (GE Medical Systems) us-
ing a standard head coil. Routine, weekly quality-assurance
monitoring was done for field homogeneity, eddy current
compensation and image quality, and there were procedures
in place for daily signal-to-noise measurement in the head coil
using a standard phantom. A scout sequence was run for each
participant to achieve similar slice positioning, and T1- and 
T2-weighted image sets were acquired in the axial plane. The
T1-weighted sequence was a 3-dimensional inversion 
recovery–prepped axial spoiled gradient-recalled acquisition
in steady state sequence (repetition time [TR] 12.3 ms, echo
time [TE] 5.4 ms, flip angle 20°, slice thickness 1.5 mm, field of
view 24 cm, matrix 256 × 256, 124 slices, acquisition time 9:47
min). The T2-weighted sequence was an axial double-echo fast
spin echo (FSE) multiplanar sequence with flow compensa-
tion (TR 3000 ms, flip angle 90°, slice thickness 3.0 mm, field
of view 24 cm, matrix 256 × 160, 60 slices, acquisition time 10:35
min) to provide both T2-weighted (TE 70 ms) and proton den-
sity–weighted (TE 28 ms) images. The FSE was zero-padded in
the phase-encoding direction from 160 to 256. Coregistered sets
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of T1 and dual-echo FSE were used to perform a multivariate
classification of 3 contrast channels. Parameters were optimized
to show grey and white matter with good contrast and to yield
reproducible segmentation with an automated program. The
entire exam was typically completed in 20 minutes.
Analysis of brain volume by MRI
Brain volumetric assessments were made using a suite of
programs developed at the University of North Carolina
(www .cs.unc.edu/~gerig/soft.html). The MRI data were an-
alyzed in a multistep process that was designed to facilitate
volumetric analysis. After skull-stripping and correction for
magnetic resonance bias inhomogeneity were performed in-
dividually for each channel, we interpolated the baseline 
T1-weighted data to an isotropic 1 × 1 × 1 mm3 grid and regis-
tered the data to the International Consortium for Brain Map-
ping probabilistic brain atlas, so that all brains were analyzed
and displayed in a standard coordinate system. The dual-
echo T2-weighted data were registered to the T1-weighted
data, and all images were analyzed with a 3-channel segmen-
tation, which used an automatic, atlas-based brain tissue seg-
mentation program (Expectation Maximization Segmenta-
tion) to separate brain tissue into grey matter, white matter
and CSF.29 The probabilistic brain atlas driving the tissue seg-
mentation utilizes Talairach-based box parcellation that di-
vides left from right hemispheres and coarsely represents the
frontal, temporal, occipital and parietal lobes.30 Atlas registra-
tion overlays these boxes onto each scan, thereby creating a
fully automatic brain parcellation for each data set. We mea-
sured ventricular volume by use of an automated level-set
evolution method. All measurements were performed with-
out knowledge of the participant’s diagnosis.
Most of the tools used were fully automatic (atlas registra-
tion and intermodality registration, brain tissue segmenta-
tion, parcellation) or automated with minimal user interac-
tion (initialization of ventricle segmentation), which makes
the procedures robust against rater drift. We calculated the
intraclass correlation coefficient for the only manual process
using a sample set of 5 data sets replicated 3 times, which re-
sulted in 15 image data sets. The trained expert user (M.E.S.),
who performed all measurements in this study, applied the
ventricular volume tool to this set of 15 images. The intraclass
correlation coefficient for the ventricular volume measure-
ment process was 0.999, demonstrating excellent intrarater
reliability. Our analysis was limited to the relatively large
structures that can be measured with a high degree of mea-
surement precision (Fig. 1).
Statistical analyses
We performed all statistical analyses using SAS 9.1. We used
descriptive statistics and data plots to look for outliers and
group differences in baseline characteristics. We examined the
intracranial volume, CSF and lateral ventricle volumes using a
general linear model that was adjusted for age and sex. The
dependent variable was volume, and the independent vari-
ables were diagnostic group, age and sex. We controlled for
age because it is a strong predictor of brain volume in chil-
dren.31To control the rate of type I errors, we required that the
test of diagnosis group (2 degrees of freedom) be significant at
the α = 0.05 level before the 2-way contrasts between groups
were interpreted.
We performed tests concerning lobe and tissue volume by
standard mixed-models analyses with repeated-measures over
a spatial domain (regional brain volumes). Each participant
had 16 repeated measures, which were designated by a combi-
nation of 3 independent variables: lobe (frontal, temporal, pari-
etal, occipital), tissue type (grey or white) and hemisphere (left
or right). The dependent variable was regional volume,
whereas the independent variables included lobe, tissue, hemi-
sphere and diagnosis group; we included all 2-, 3- and 4-way
interactions between these 4 variables. In addition, we in-
cluded age and intracranial volume as control variables in the
regression analyses, along with the interactions between each
of these variables and region and tissue. We also included in-
telligence quotient and sex as covariates in the model; these
variables did not contribute significantly or change the results,
so they were not included in the final analyses.
We performed initial comparisons of total brain, grey and
white matter volumes between the 2 diagnostic groups and be-
tween each of the diagnostic groups and the healthy control
group. Because we found no difference in the volumes of the
brain structures between the EOMD and control group, we
combined these groups. The subsequent analyses of regional
volumes compared the EOSS group with the combined EOMD
and control group. This increased the sample size of partici-
pants included as controls, yet it is consistent with our initial




Fig. 1: False colour of grey and white matter segmentation. Repre-
sentative participant magnetic resonance imaging data following im-
age registration and segmentation showing the axial (A), sagittal (B)
and coronal (C) views, with 3-dimensional surface rendering (D). An
atlas-based 3-channel tissue segmentation program (Expectation
Maximization Segmentation) was used to segregate white matter
(puce), grey matter (gold) and cerebrospinal fluid (blue).
To adjust for heteroscedasticity within the regions of inter-
est, we computed empirical estimates using the empirical op-
tion of SAS Proc Mixed32  because lobes and other small struc-
tures can have different means and variances. To adjust for
systematic variances in the regional brain volumes, we com-
puted empirical estimates of the standard erros with a correc-
tion factor for small samples using SAS Proc Mixed.32,33
Results
Participants
In total, we included 15 patients with schizophrenia spec-
trum disorder (schizophrenia or schizoaffective disorder,
hereafter referred to as schizophrenia), 14 patients with affec-
tive psychoses and 17 healthy controls. Twenty-nine of the 
50 participants in the psychosis-treatment study (58%) com-
pleted imaging . Reasons for not completing the imaging in-
cluded metal in their body or braces (n = 5), too psychotic to
tolerate the MRI procedure (n = 4), aged less than 12 years 
(n = 4) and declined to participate (n = 8). In addition, the im-
ages of 5 patients (3 with EOSS and 2 with EOMD) with were
excluded because of inadequate image quality for segmenta-
tion owing to motion artifacts during the scan procedure. 
The final analyzed sample included 12 patients with
schizo phrenia (6 with schizoaffective disorder), 12 patients
with affective psychosis (7 with psychotic depression, 5 with
bipolar disorder) and 17 controls (Table 1). Age did not sig-
nificantly differ between the groups. There were fewer male
participants in the EOMD group than in either the EOSS or
control groups (Table 1).
Brain volumes
There was no significant difference in intracranial volume
across the 3 groups after adjustment for age and sex (F2,35 =
1.78, p = 0.18). The distribution of grey matter, white matter
and CSF volumes proportional to total intracranial volume in
each group is shown in Figure 2. Total, grey matter and white
matter volumes adjusted for age and intracranial volume are
provided in Table 2. After adjustment for age and intracranial
volume, the EOSS group had reduced total brain volume
compared with the healthy control group (–2.2%, t36 = –3.88, 
p = 0.001) and the EOMD group (–2.0%, t36 = –3.88, p = 0.002).
After adjustment, the EOSS group had reduced grey matter
compared with the healthy control group (–4.0%, t36 = –3.13, 
p = 0.001) and EOMD group (–4.5%, t36 = –3.29, p = 0.019), but
there was no differences in white matter volume (data not
shown). In contrast, there were no differences in adjusted 
total brain volume, grey matter or white matter between the
EOMD group and the healthy control group (p = 0.40 to 0.48).
All subsequent comparisons involved the EOSS group and
the combined control group (EOMD plus healthy controls;
Table 2). The EOSS group had significantly reduced adjusted
El-Sayed et al.
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Table 1: Demographic and clinical characteristics of participants
Group; mean (SD)*
Characteristic Schizophrenia, n = 12 Mood disorder, n = 12 Healthy control, n = 17
Age, yr, mean (SD) [range] 16.2 (2.5) 14.9 (1.9) 15.9 (2.1)
[12.1–19.7] [12.9–17.9] [12.1–19.1]
Head circumference, mm 561.0 (14.8) 531.5 (15.6) 555.5 (27.2)
Intracranial volume, mm3 1341.8 (108.6) 1235.7 (142.1) 1365.7 (167.4)
Male, no. (%) of participants 9 (75) 4 (33) 10 (59)
Nonwhite, no. (%) of participants 6 (50) 3 (25) 8 (47)
Age at onset, yr 13.55 (4.27) 12.83 (2.79) —
Duration of illness, yr 2.60 (2.67) 2.03 (1.81) —
Previous hospitalizations, no. 1.09 (1.58) 0.50 (0.67) —
Medication history, no. (%) of participants —
Previous typical antipsychotic 7 (58) 0
Previous risperidone 8 (67) 4 (33)
Previous olanzapine 6 (50) 3 (25)
Previous other atypical antipsychotic 0 1 (8)
Previous antidepressant medications 6 (50) 6 (50)
Previous mood stabilizer 2 (17) 1 (8)
Symptom severity —
Childhood psychiatric rating scale,
positive symptoms
29.45 (1.37) 31.42 (6.44)
Childhood psychiatric rating scale,
negative symptoms
24.18 (14.53) 19.08 (12.72)
Brief psychiatric rating for children,
total score
73.2 (14.7) 74.7 (11.6)
Depression items 9.3 (4.9) 12.7 (4.4)
Mania items 12.1 (4.3) 14.0 (4.0)
Baseline intelligence quotient 79.1 (14.9) 98.2 (12.8)
SD = standard deviation.
*Unless otherwise indicated.
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total brain volume (–2.1%, t36 = –3.70, p < 0.001) and total grey
matter (–4.2%, t36 = –3.42, p = 0.002) compared with the com-
bined control group. There were no significant differences
between groups for white matter volume (t36 = 1.13, p = 0.27).
We observed similar relations for adjusted total and grey
matter volumes in the frontal and parietal lobes, with the
EOSS group having significantly smaller volumes than the
combined control group (Fig. 3). There was no differences be-
tween the EOSS group and the combined control group for
adjusted volume in the temporal and occipital lobes or for
adjusted white matter volume in any lobe. The EOSS group
had significantly greater adjusted CSF volume than the com-
bined control group (12.6%, t36 = 4.32, p < 0.001). However,
the adjusted lateral ventricle volume was not different be-
tween the EOSS group and the combined control group (t36 =
0.74, p = 0.46).
Discussion
In this study, we report total and regional deficits of grey
matter volume in psychotic adolescents with schizophrenia
but not in psychotic adolescents with mood disorder. The
deficits in grey matter volume were significant in the frontal
and parietal lobes. Our results suggest that structural brain
changes may be specifically associated with schizophrenia
but not generally associated with psychotic symptoms.
Our results in the EOSS group are largely consistent with
earlier results from childhood-onset schizophrenia and first-
episode schizophrenia studies which reported that grey matter
deficits are most prominent in parietal cortices.4,8,9 In contrast to
longitudinal studies in childhood-onset and adult-onset schiz-
ophrenia, we did not observe significant grey matter deficits in
the temporal lobe.8,9 The discrepancy in the temporal lobe
could also reflect imaging earlier in the disease process or rela-
tively small differences that are only apparent in large sam-
ples. Alternatively, divergent results may reflect differences in
imaging methods or phenotypic variability in schizophrenia.
Our findings in the schizophrenia group are consistent
with those of Nakamura and colleagues,23 with caveats. We
did not detect any differences in grey matter volume in pa-
tients with affective psychoses, which contradicts the find-
ings of the baseline scan in their sample. However, our find-
ings are consistent with their 18-month follow-up data,
which suggests that the duration of illness may be critical in
determining brain volumetric deficits. The mean duration of
illness in our sample was 24 months. Our results are also con-
sistent with other comparative studies of first-episode schizo-
phrenia and first-episode affective psychosis.18,20–22,24Although
a recent study found several grey matter deficits that ap-
peared to be unique to EOSS, it also suggested that left me-
dial frontal grey matter deficits may be common to both ado-
lescents with EOSS and first-episode bipolar psychosis.34
Limitations
The greatest limitation of our study is the small sample size,
which limits our ability to detect small differences in volume.
We also lacked the power to rigorously test the correlations
between cortical volume and clinical and symptomatic char-
acteristics. These results do not preclude the existence of
smaller or more focal differences between either psychotic
group and healthy controls that might be revealed with other
methods or a larger sample size. A strength of our study is
that we focused on youth with adolescent-onset schizophre-
nia rather than on the more rare childhood-onset disorder.
Furthermore, most of the participants were not resistant 




































































Controls Mood Disorder Schizophrenia
Healthy control Mood disorder Schizophrenia
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A Grey matter volume : intracranial volume
B White matter volume : intracranial volume
C Cerebrospinal fluid : intracranial volume
Fig. 2: Distribution of brain volume ratios by group with no correc-
tion for age. (A) Ratio of grey matter to intracranial volume, (B) ratio
of white matter to intracranial volume and (C) ratio of cerebrospinal
fluid to intracranial volume.
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Fig. 3: Differences between patients with schizophrenia and other participants (healthy controls and pa-
tients with mood disorder). Percentages have been adjusted by age and intracranial volume. The p values
are for the comparisons between the adjusted lobar volumes in the early-onset schizophrenia-spectrum
disorders group and in the combined control group (early-onset mood disorder group plus healthy controls)
for the specific lobes.  
Table 2: Group means and differences between schizophrenia patients and combined controls (mood disorder and healthy controls) for grey and
white matter volumes
Group; brain volume, mm3, mean* (SE)
Schizophrenia v.
mood disorder and healthy control
participants
Brain region Schizophrenia, n = 12 Mood disorder, n = 12 Healthy control, n = 17 Mood + control, n = 29 Difference SE % p value
Intracranial 1303.0 (37.0) 1273.7 (37.9) 1360.9 (30.3) 1317.3 (23.9) –14.4 25.4 –1.1 0.75
Cerebrospinal fluid 223.5 (4.5) 197.9 (4.8) 199.0 (3.8) 198.7 (3.1) 25.0 5.4 12.6 < 0.001
Lateral ventricle 13.3 (1.1) 13.4 (1.2) 11.2 (1.0) 12.3 (0.7) 1.0 1.4 8.1 0.46
Total grey and
white matter
1094.5 (5.6) 1116.4 (4.4) 1118.6 (2.6) 1116.4 (2.5) –23.0 6.2 –2.1 < 0.001
Frontal lobe 554.5 (4.0) 564.4 (3.1) 571.0 (3.1) 567.1 (2.2) –13.2 4.7 –2.3 0.008
Occipital lobe 146.9 (2.6) 150.3 (2.2) 148.6 (2.5) 149.3 (1.7) –2.5 3.2 –1.7 0.44
Parietal lobe 204.4 (1.9) 212.1 (2.4) 208.6 (1.9) 210.1 (1.5) –5.9 2.5 –2.8 0.024
Temporal lobe 188.6 (3.4) 189.5 (2.3) 190.5 (2.1) 189.8 (1.5) –1.3 4.0 –0.7 0.74
Grey matter 647.4 (7.6) 676.6 (5.3) 674.7 (2.9) 675.0 (2.8) –28.3 8.3 –4.2 0.002
Frontal lobe 292.1 (4.2) 306.6 (3.1) 308.2 (1.9) 307.1 (1.7) –15.3 4.7 –5.0 0.002
Occipital lobe 113.3 (2.2) 117.2 (1.7) 116.5 (1.9) 116.7 (1.3) –3.6 2.6 –3.1 0.18
Parietal lobe 117.4 (2.1) 126.7 (1.5) 123.4 (1.4) 124.9 (1.0) –7.7 2.4 –6.2 0.003
Temporal lobe 124.6 (2.4) 126.1 (1.9) 126.6 (1.5) 126.2 (1.1) –1.7 2.8 –1.4 0.55
White matter 447.1 (4.1) 439.8 (3.9) 444.0 (2.1) 441.4 (2.1) 5.3 4.7 1.2 0.27
Frontal lobe 262.4 (3.3) 257.7 (2.6) 262.9 (2.1) 260.0 (1.6) 2.1 3.7 0.8 0.58
Occipital lobe 33.7 (0.9) 33.2 (0.9) 32.1 (1.0) 32.6 (0.7) 1.0 1.2 3.2 0.37
Parietal lobe 87.0 (1.2) 85.4 (1.3) 85.1 (0.8) 85.2 (0.7) 1.7 1.4 2.0 0.24
Temporal lobe 64.1 (1.3) 63.4 (1.4) 63.9 (0.9) 63.6 (0.8) 0.4 1.6 0.6 0.82
SE = standard error of the mean.
*Adjusted for age and intracranial volume.
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Conclusion
The finding of grey matter reduction in patients with schizo-
phrenia but not in those with mood disorder suggests that
grey matter deficits may be a specific feature of schizophrenia
rather than a general feature of psychosis. This may mean that
volumetric deficits are related more to negative and cognitive
symptoms rather than to positive symptoms. A better under-
standing of the underlying pathophysiology of schizophrenia
and optimized design of next-generation treatment will re-
quire larger samples from multisite consortiums and more
uniform analysis procedures.
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PRISTIQ is indicated for the symptomatic relief of major 
depressive disorder. The short-term effi cacy of PRISTIQ 
(desvenlafaxine succinate extended-release tablets) has been 
demonstrated in placebo-controlled trials of up to 8 weeks. 
The most commonly observed adverse events associated with the 
use of PRISTIQ (at an incidence ³5% and at least twice the rate 
of placebo) were nausea (22%), dizziness (13%), hyperhidrosis 
(10%), constipation (9%), and decreased appetite (5%). 
PRISTIQ is not indicated for use in children under the age of 18. 
PRISTIQ is contraindicated in patients taking monoamine 
oxidase inhibitors (MAOIs, including linezolid, an antibiotic) 
or in patients who have taken MAOIs within the preceding 
14 days due to risk of serious, sometimes fatal, drug
interactions with selective serotonin reuptake inhibitor 
(SSRI) or serotonin norepinephrine reuptake inhibitor 
(SNRI) treatment or with other serotonergic drugs. These 
interactions have been associated with symptoms that include 
tremor, myoclonus, diaphoresis, nausea, vomiting, fl ushing, 
dizziness, hyperthermia with features resembling neuroleptic 
malignant syndrome, seizures, rigidity, autonomic instability 
with possible rapid fl uctuations of vital signs, and mental 
status changes that include extreme agitation progressing to 
delirium and coma. Based on the half-life of desvenlafaxine 
succinate, at least 7 days should be allowed after stopping 
desvenlafaxine succinate and before starting an MAOI.
PRISTIQ is contraindicated in patients demonstrating 
hypersensitivity to desvenlafaxine succinate extended-
release, venlafaxine hydrochloride or to any excipients in the 
desvenlafaxine formulation. Concomitant use of PRISTIQ with 
products containing venlafaxine is not recommended.
Recent analyses of placebo-controlled clinical trial safety 
databases from selective serotonin reuptake inhibitors 
(SSRIs) and other newer antidepressants suggest that 
use of these drugs in patients under the age of 18 may 
be associated with behavioural and emotional changes, 
including an increased risk of suicide ideation and 
behaviour over that of placebo. 
The small denominators in the clinical trial database, as 
well as the variability in placebo rates, preclude reliable 
conclusions on the relative safety profiles among the drugs 
in the class. There are clinical trial and post-marketing reports 
with SSRIs and other newer antidepressants  in both pediatrics ,
and adults, of severe agitation-type events that include: 
akathisia, agitation, disinhibition, emotional lability, hostility, 
aggression and depersonalization. In some cases, the events 
occurred within several weeks of starting treatment. 
Rigorous clinical monitoring for suicide ideation or other 
indicators of potential for suicide behaviour is advised 
in patients of all ages, especially when initiating therapy 
or during any change in dose or dosage regimen. 
This includes monitoring for agitation-type emotional 
and behavioural changes. 
Patients currently taking PRISTIQ should NOT be 
discontinued abrup lt y, due to ri ks  of discontinuation 
symptoms. At the time that a medical decision is made 
to discontinue an SSRI or other newer antidepressant 
drug, a gradual reduction in the dose, rather than an 
abrupt cessation is recommended.
Reference: 1. Wy het  Canada. PRISTIQ Product Monograph  , August 2009.
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